Literature DB >> 22866123

Deleted in liver cancer protein family in human malignancies (Review).

D Lukasik1, E Wilczek, A Wasiutynski, B Gornicka.   

Abstract

The Deleted in Liver Cancer (DLC) protein family comprises proteins that exert their function mainly by the Rho GTPase-activating protein (GAP) domain and by regulation of the small GTPases. Since Rho GTPases are key factors in cell proliferation, polarity, cytoskeletal remodeling and migration, the aberrant function of their regulators may lead to cell transformation. One subgroup of these proteins is the DLC family. It was found that the first identified gene from this family, DLC1, is often lost in hepatocellular carcinoma and may be involved as a tumor suppressor in the liver. Subsequent studies evaluated the hypothesis that the DLC1 gene acts as a tumor suppressor, not only in liver cancer, but also in other types of cancer. Following DLC1, two other members of the DLC protein family, DLC2 and DLC3, were identified. However, limited published data are available concerning the role of these proteins in malignant transformation. This review focuses on the structure and the role of DLC1 and its relatives in physiological conditions and summarizes data published thus far regarding DLC function in the neoplastic process.

Entities:  

Year:  2011        PMID： 22866123      PMCID： PMC3408103          DOI： 10.3892/ol.2011.345

Source DB:  PubMed          Journal:  Oncol Lett        ISSN： 1792-1074            Impact factor:   2.967


  67 in total

1.  Solution structure of a conserved C-terminal domain of p73 with structural homology to the SAM domain.

Authors:  S W Chi; A Ayed; C H Arrowsmith
Journal:  EMBO J       Date:  1999-08-16       Impact factor: 11.598

2.  Elongation factor-1alpha stabilizes microtubules in a calcium/calmodulin-dependent manner.

Authors:  R C Moore; N A Durso; R J Cyr
Journal:  Cell Motil Cytoskeleton       Date:  1998

3.  DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1.

Authors:  I O Ng; Z D Liang; L Cao; T K Lee
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

4.  The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells.

Authors:  Steve Goodison; Jing Yuan; Derek Sloan; Ryung Kim; Cheng Li; Nicholas C Popescu; Virginia Urquidi
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

5.  The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation.

Authors:  T J Seng; J S W Low; H Li; Y Cui; H K Goh; M L Y Wong; G Srivastava; D Sidransky; J Califano; R D M Steenbergen; S Y Rha; J Tan; W-S Hsieh; R F Ambinder; X Lin; A T C Chan; Q Tao
Journal:  Oncogene       Date:  2006-07-24       Impact factor: 9.867

6.  Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.

Authors:  Ming Guan; Xiaoling Zhou; Nikolaos Soulitzis; Demetrios A Spandidos; Nicholas C Popescu
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

7.  Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities.

Authors:  Xiaolan Qian; Guorong Li; Holly K Asmussen; Laura Asnaghi; William C Vass; Richard Braverman; Kenneth M Yamada; Nicholas C Popescu; Alex G Papageorge; Douglas R Lowy
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-15       Impact factor: 11.205

8.  Chromosome 13q12 encoded Rho GTPase activating protein suppresses growth of breast carcinoma cells, and yeast two-hybrid screen shows its interaction with several proteins.

Authors:  Ganachari M Nagaraja; Raj P Kandpal
Journal:  Biochem Biophys Res Commun       Date:  2004-01-16       Impact factor: 3.575

9.  Effects of structure of Rho GTPase-activating protein DLC-1 on cell morphology and migration.

Authors:  Tai Young Kim; Kevin D Healy; Channing J Der; Noah Sciaky; Yung-Jue Bang; Rudy L Juliano
Journal:  J Biol Chem       Date:  2008-09-11       Impact factor: 5.157

Review 10.  DLC-1:a Rho GTPase-activating protein and tumour suppressor.

Authors:  Marian E Durkin; Bao-Zhu Yuan; Xiaoling Zhou; Drazen B Zimonjic; Douglas R Lowy; Snorri S Thorgeirsson; Nicholas C Popescu
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310
View more
  25 in total

1.  DLC2 inhibits development of glioma through regulating the expression ratio of TAp73α/TAp73β.

Authors:  Chao Cheng; Suyin Feng; Jiantong Jiao; Weiyi Huang; Jin Huang; Long Wang; Wei Jiang; Chen Jiang; Minchao Dai; Zheng Li; Rui Zhang; Jun Sun; Junfei Shao
Journal:  Am J Cancer Res       Date:  2018-07-01       Impact factor: 6.166

2.  Effects of DLC1 Deficiency on Endothelial Cell Contact Growth Inhibition and Angiosarcoma Progression.

Authors:  David Sánchez-Martín; Atsushi Otsuka; Kenji Kabashima; Taekyu Ha; Dunrui Wang; Xiaolan Qian; Douglas R Lowy; Giovanna Tosato
Journal:  J Natl Cancer Inst       Date:  2018-04-01       Impact factor: 13.506

3.  Functional cross-talk between ras and rho pathways: a Ras-specific GTPase-activating protein (p120RasGAP) competitively inhibits the RhoGAP activity of deleted in liver cancer (DLC) tumor suppressor by masking the catalytic arginine finger.

Authors:  Mamta Jaiswal; Radovan Dvorsky; Ehsan Amin; Sarah L Risse; Eyad K Fansa; Si-Cai Zhang; Mohamed S Taha; Aziz R Gauhar; Saeideh Nakhaei-Rad; Claus Kordes; Katja T Koessmeier; Ion C Cirstea; Monilola A Olayioye; Dieter Häussinger; Mohammad R Ahmadian
Journal:  J Biol Chem       Date:  2014-01-17       Impact factor: 5.157

4.  The regulation of RhoA at focal adhesions by StarD13 is important for astrocytoma cell motility.

Authors:  Bassem D Khalil; Samer Hanna; Bechara A Saykali; Sally El-Sitt; Anita Nasrallah; Daniel Marston; Marwan El-Sabban; Klaus M Hahn; Marc Symons; Mirvat El-Sibai
Journal:  Exp Cell Res       Date:  2013-12-10       Impact factor: 3.905

Review 5.  StarD13: a potential star target for tumor therapeutics.

Authors:  Leila Jaafar; Zeinab Chamseddine; Mirvat El-Sibai
Journal:  Hum Cell       Date:  2020-04-09       Impact factor: 4.174

6.  Curcumin inhibits growth of human breast cancer cells through demethylation of DLC1 promoter.

Authors:  Yufei Liu; Jun Zhou; Yuchang Hu; Junjie Wang; Chengfu Yuan
Journal:  Mol Cell Biochem       Date:  2016-11-10       Impact factor: 3.396

7.  Cooperative antiproliferative effect of coordinated ectopic expression of DLC1 tumor suppressor protein and silencing of MYC oncogene expression in liver cancer cells: Therapeutic implications.

Authors:  Xuyu Yang; Xiaoling Zhou; Paul Tone; Marian E Durkin; Nicholas C Popescu
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

Review 8.  Filling GAPs in our knowledge: ARHGAP11A and RACGAP1 act as oncogenes in basal-like breast cancers.

Authors:  Campbell D Lawson; Channing J Der
Journal:  Small GTPases       Date:  2016-09-26

Review 9.  Deleted in liver cancer-1 (DLC1): an emerging metastasis suppressor gene.

Authors:  Nicholas C Popescu; Steve Goodison
Journal:  Mol Diagn Ther       Date:  2014-06       Impact factor: 4.074

10.  CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth.

Authors:  Tai Young Kim; Sarah Jackson; Yue Xiong; Timothy G Whitsett; Janine R Lobello; Glen J Weiss; Nhan Le Tran; Yung-Jue Bang; Channing J Der
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-30       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.